| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Intercure Ltd.
$0.95
+0 (+0.07%)
Market Cap
48.00 M
EPS
0.70
P/E Ratio
1.34 $
Value Trade
3.11 K
-2.57 %
Week
3.3 %
1 Month
9.94 %
3 Month
5.62 %
6 Month
-87.28 %
5 Year
-65.03 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
72.06 K
52 Week Range
0.68 - 1.71
% held by Insiders
39.17 %
% held by Institutions
2.9 %
Enterprise Value
90.10 M
Total Shares
54.68 M
Short %
0.03 %
Float Shares
32.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intercure Ltd.
105Total events
1Upcoming
34Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▲AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INCR▲ +0.1%today
InterCure Ltd. Announces 1-for-5 Reverse Share Split
InterCure Ltd. has announced a 1-for-5 reverse share split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will adjust the number of outstanding shares and is set to take effect on August 24, 2026. The company aims to maintain its Nasdaq listing while appealing any potential delisting determination.
Read more →INCR▲ +17.4%on this news
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
InterCure Ltd. has announced a binding term sheet for a private placement financing of NIS 22 million, which may increase to NIS 54 million. The funding, led by institutional investors including the CEO, aims to support the company's growth strategy and expansion in regulated cannabis markets, particularly in Germany. The placement is subject to certain conditions, including shareholder approval.
Read more →INCR▲ +9.3%on this news
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Ltd. has completed the first tranche of its acquisition of Botanico, enhancing its portfolio with exclusive U.S. cannabis genetics and advanced technologies. Following the recent federal rescheduling of medical cannabis, the company is evaluating opportunities in regulated U.S. markets. InterCure also reports increasing demand in Germany, with plans for new product launches.
Read more →INCR▲ +5.5%on this news
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NI
InterCure Ltd. announced its financial results for 2025, reporting revenues of over NIS 270 million and a positive operating cash flow of NIS 17 million. The company noted a net loss of NIS 37 million and continued efforts to recover from the impacts of the October 7, 2023 attacks. As part of its recovery, InterCure resumed production and launched numerous new medical cannabis products during the year. Additionally, significant strategic partnerships and global market expansion were highlighted, particularly in Germany, marking a positive outlook going forward.
Read more →INCRInterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement NEW YORK and
InterCure Ltd. received a notification from Nasdaq indicating its ordinary shares do not meet the minimum bid price requirement of $1.00 per share. The company has a 180-day compliance period to regain compliance, with options for an additional period if necessary. InterCure plans to monitor its share price closely and is considering a reverse share split to address the issue. Despite the challenge, the company's shares will continue to trade on the Nasdaq Global Market during this timeframe.
Read more →INCR▼ -5.8%on this news
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash 1 of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Ad
InterCure Ltd. reported preliminary estimated revenue of NIS 265 million for 2025, indicating an 11% increase from 2024. The company also achieved its twelfth consecutive half-year of positive Adjusted EBITDA, reflecting overall growth and operational success. Notably, the second half of 2025 saw a nearly 20% revenue increase compared to the same period in the previous year, driven partly by the company's entry into the German market. InterCure plans to further expand its operations in Germany and other markets as part of its global growth strategy.
Read more →INCRNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2025 To the shareholders of InterCure Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of the shareholders of Inter
InterCure Ltd. has announced its Annual General Meeting of shareholders, scheduled for December 30, 2025, at its legal office in Tel Aviv, Israel. Shareholders of record as of December 2, 2025, will be eligible to attend and vote at this meeting. The agenda for the meeting has not been disclosed, and shareholders are encouraged to participate, either in person or via proxy. Proxies must be submitted by December 29, 2025, to ensure representation at the meeting.
Read more →INCRInterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation Agreements formalize research partnership combining InterCure's global pharmaceutic
InterCure Ltd. has signed strategic investment and collaboration agreements with Cannasoul R&D Ltd., formalizing a partnership to develop cannabis therapeutics. This includes a 28% ownership stake in Cannasoul with an exclusive option to increase to 51%. The timing aligns with reports of the U.S. administration considering cannabis rescheduling, which may unlock new opportunities. The partnership will leverage Cannasoul's research capabilities and appoint Prof. Dedi Meiri to enhance scientific oversight.
Read more →INCRInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating
InterCure Ltd. announced its financial results for the first half of 2025, reporting revenues of NIS 130 million and a positive operating cash flow of NIS 12 million. This performance reflects the company's ability to maintain profitability through challenging environments, with a continuous record of positive Adjusted EBITDA for eleven halves. The company is also pursuing an acquisition of ISHI and is watching regulatory changes in the U.S. cannabis market, which they believe will provide growth opportunities. However, ongoing conflicts pose potential risks to their operations in Israel.
Read more →INCRInterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strateg
InterCure Ltd. has announced its strategic acquisition of ISHI (Botanico Ltd.), enhancing its access to premium U.S. cannabis technology and brands. This acquisition marks a significant milestone in InterCure's expansion strategy, coinciding with favorable regulatory momentum in the U.S. cannabis market. InterCure will gain partnerships with top-tier cannabis operators and access to innovative cultivation technologies, which are expected to enhance operational capabilities and market competitiveness. The transaction will close in Q1 2026, pending regulatory approvals.
Read more →INCRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 2024 results were affected by damages to our southern facility caused
InterCure has announced its financial results for FY2024, reporting revenues of NIS 239 million and an Adjusted EBITDA of NIS 24 million. Despite the adverse effects from damages caused by the October 7 terrorist attack and the ongoing war in Gaza, the company achieved profitability for the eighteenth and nineteenth consecutive quarters. InterCure has also secured funding for facility recovery and plans to expand its strategic partnership with Cookies in Europe. The company is optimistic about a strong start to Q1 2025, expecting continued growth.
Read more →INCRInterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza....
InterCure announced its FY2024 results, reporting revenues of NIS 239 million and an Adjusted EBITDA of NIS 24 million. The results were affected by damages from the October 7 terrorist attack and the ongoing war in Gaza. Despite these challenges, the company expects a strong start to 2025 with over 25% sequential growth and has expanded its partnership with Cookies™ into Germany. The company remains focused on recovery and international expansion.
Read more →INCRInterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak NEW YORK &
InterCure Ltd. announced the appointment of Alexander Rabinovich as the new Chairman of the Board, succeeding Ehud Barak who is stepping down. Rabinovich, who has been the CEO for the past five years, has overseen significant growth and strategic partnerships for the company. InterCure recently completed financing to support the recovery of its Nir Oz facility, which has been impacted by ongoing conflicts. The company is focused on restoring operations and expanding its product portfolio.
Read more →INCRInterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr. Ehud Barak will step down as...
InterCure Ltd. announced that Alexander Rabinovich will replace Ehud Barak as Chairman of the Board, effective February 13, 2025. Barak, who has served for six years, is stepping down to pursue personal endeavors. The company has secured approximately $18.2 million in financing to support the recovery of its Nir Oz facility, which was impacted by recent conflicts. Rabinovich emphasizes the company's commitment to patient care and international expansion.
Read more →INCRNOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 To the shareholders of Intercure Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting ") of the sharehol
Intercure Ltd. has announced an upcoming Extraordinary General Meeting for shareholders scheduled on January 27, 2025. The meeting will take place at the offices of the Company's attorneys in Bnei Brak, Israel. Shareholders as of December 27, 2024, will be able to attend and vote on various matters, with specific procedures outlined for proxy voting. The company's board has recommended shareholders vote "FOR" the proposed items.
Read more →INCR▲ +11.2%on this news· ran to +34% by day 1
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025 To the shareholders of InterCure Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting ") of the sharehol
InterCure Ltd. has announced an Extraordinary General Meeting of its shareholders scheduled for January 27, 2025, at the offices of Doron Tikotzky Kantor Gutman & Amit Gross in Bnei Brak, Israel. Shareholders as of December 27, 2024, will be entitled to notice of and vote at the meeting. The Company’s Board of Directors recommends that shareholders vote in favor of the proposed items on the agenda. The notice details the procedures for voting, including proxy submissions for those unable to attend in person.
Read more →INCR▲ +11.2%on this news· ran to +34% by day 1
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-wa
InterCure has successfully secured NIS 66 million in funding to aid the recovery of its Nir Oz Facility, which could increase to NIS 107 million. Key shareholders including the CEO are participating in the funding, which also includes a loan from a major Israeli bank. This funding is expected to facilitate a return to profitability and support the company's expansion into international markets such as Germany, the UK, and Australia. The company anticipates additional compensation from Israeli authorities for war-related damages, further aiding its recovery efforts.
Read more →INCR▲ +5.2%on this news
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2024 To the shareholders of Intercure Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of the shareholders of Inter
Intercure Ltd. has announced its Annual General Meeting scheduled for December 30, 2024, taking place at the offices of its attorneys in Bnei Brak, Israel. Shareholders must be on record by December 2, 2024, to gain access to vote on various agenda items. Proxy voting details are provided for those unable to attend in person, enhancing shareholder participation. The Board of Directors recommends voting in favor of all proposed items at the meeting.
Read more →INCRNOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON OCTOBER 28, 2024 To the shareholders of InterCure Ltd.: Notice is hereby given that an Extraordinary General Meeting (the " Meeting ") of the sharehol
InterCure Ltd. has announced an Extraordinary General Meeting for shareholders to take place on October 28, 2024. The agenda includes the re-election of external directors, Ms. Lennie Michelson Grinbaum and Mr. Gideon Hirshfeld, along with approval for stock options and a new Compensation Policy. Shareholders as of September 20, 2024, will be entitled to vote at the meeting. The company aims to comply with Nasdaq listing standards and enhance its governance framework.
Read more →INCRInterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA 1 of NIS 21 mi
InterCure announced its financial results for the first half of 2024, reporting revenues of NIS 126 million and an adjusted EBITDA of NIS 21 million. Despite facing revenue impacts from a terrorist attack and the war in Gaza, the company has maintained profitability for 17 consecutive quarters. InterCure is set to expand its strategic partnership with Cookies to Germany and anticipates significant growth in the European market, expecting to launch new products later this year. Restoration efforts for the Southern Facility are ongoing, supported by compensation from Israeli authorities.
Read more →INCR▲ +6.1%on this newsshared move
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany InterCure expands its European footprint to launch Cookies Corners licensed pharmacies in Germany alongside differentiated online platfor
InterCure Ltd. has announced an expansion of its strategic partnership with the globally recognized cannabis brand Cookies into Germany. This agreement will enable InterCure to cultivate, manufacture, and distribute Cookies-branded products in eight licensed pharmacies across major German cities. With recent legislation impacting the medical cannabis market leading to a substantial increase in prescriptions, this partnership aims to capitalize on the growing demand. The collaboration signifies a major step in expanding InterCure's footprint in Europe alongside their existing initiatives in the UK and Austria.
Read more →INCRInterCure Provides Update Following Class Action Dismissal The Tel Aviv-Yafo District Court ruled in favor of InterCure and the defendants, dismissing the suit and ordering plaintiffs to pay legal expenses NEW YORK and
InterCure Ltd. announced that the Tel Aviv-Yafo District Court dismissed a class action lawsuit against it and other defendants. The court's ruling, dated May 16, 2024, orders the plaintiffs to pay the defendants' legal costs. This decision underscores InterCure's robust legal standing in the Israeli cannabis market and alleviates concerns regarding the alleged violations of advertising regulations. The company continues to uphold its position as a leading and profitable cannabis producer outside North America.
Read more →INCRInterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA 1 of NIS 61 million (Approximately 17% of re
InterCure announced its FY2023 financial results, reporting revenues of NIS 356 million and an adjusted EBITDA of NIS 61 million, up from NIS 51 million in preliminary results. The company experienced challenges in H2 2023 due to damages from a terrorist attack and the ongoing war in Gaza. Despite these issues, InterCure has maintained profitability for its fourteenth and fifteenth consecutive quarters and anticipates launching its first products in Germany soon. The company is also set to achieve sequential double-digit growth throughout 2024.
Read more →INCRInterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBIDTA of over NIS 50 million Revenues for H2 2023 were affected by damages caused by the terrorist attack on
InterCure Ltd. has announced its preliminary estimated revenues for 2023, projecting NIS 351 million and an EBITDA of over NIS 50 million. Despite challenges from a terrorist attack and the war in Gaza affecting the second half of the year, the company highlighted its continuing profitability with positive EBITDAs in Q3 and Q4. InterCure is also preparing for product launches in Germany and anticipates double-digit growth in 2024, bolstered by favorable regulatory developments for cannabis. Compensation from Israeli authorities for damages incurred has already begun with advanced payments received.
Read more →INCR▼ -7.3%on this news
InterCure Provides an Update Regarding Nir Oz Facility NEW YORK, and
InterCure Ltd. has provided an update on its Southern Israel facility in Kibbutz Nir Oz amidst the ongoing war situation that began on October 7, 2023. Currently, parts of the site are being used by the Israel Defense Forces, limiting access. Despite these challenges, the company is proceeding with restoration efforts and is in talks for compensation from the Israeli government for damages incurred. InterCure remains committed to supporting patient communities affected by the conflict and plans to release financial results for 2023 by April 2024.
Read more →INCRInterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain NEW YORK, and
InterCure Ltd. has announced a definitive agreement to acquire Leon Pharm, a pharmacy chain in Israel that specializes in medical cannabis. This move aligns with InterCure's strategy to expand its distribution network amid new medical cannabis reforms in Israel. The transaction involves the issuance of 1,755,000 to 1,845,000 shares to the sellers, contingent on the company's share price at closing. Approval from regulatory bodies is required for the transaction to proceed.
Read more →INCRNOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 14, 2023 To the shareholders of Intercure Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of the shareholders of Inter
Intercure Ltd. has announced its Annual General Meeting (AGM) to be held on December 14, 2023, at its attorneys' offices in Bnei Brak, Israel. Shareholders will vote on the re-election of board members and the re-appointment of the company's auditors for the fiscal year ending December 31, 2023. The meeting will also include a review of the financial statements for the previous year and any other business that may arise. The company encourages shareholders to attend or submit proxies for voting.
Read more →INCRInterCure Wins Cannolam Arbitration Proceeding NEW YORK, and
InterCure Ltd. has successfully completed arbitration proceedings against minority shareholders of its subsidiary, Cannolam Ltd. The arbitrator ruled largely in favor of InterCure, determining that Cannolam owes significant financial amounts to the company. As a result, InterCure now controls 100% of Cannolam's shares, which includes exclusive rights to the 'Cookies' brand. This outcome is expected to bolster InterCure's market position as a leading medical cannabis provider in Israel and beyond.
Read more →INCRInterCure Provides an Update Regarding the Security Situation in Israel NEW YORK, and
InterCure Ltd. provided an update on the security situation in Israel following recent terrorist attacks from Hamas, which have impacted the company's operations. The Southern Israel Site, located near the Gaza Strip, has been closed and its condition is unknown, while other facilities continue to operate normally. The company is committed to supporting local communities affected by the violence and is anticipating government compensation for damages. Uncertainties remain regarding the long-term financial implications of the conflict.
Read more →INCR▲ +6.6%on this news
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY Achieved record revenues of NIS 209 million ($75 million) 1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149
InterCure Ltd. reported recording revenues of NIS 209 million ($75 million) for the first half of 2023, reflecting a YOY growth of over 14%. The company achieved a strong annualized revenue run rate of NIS 417 million ($149 million) and a positive EBITDA of NIS 30 million ($11 million). Notably, market share growth was supported by the successful launch of more than 20 new products. Furthermore, positive cash flow in the second quarter strengthens the company's financial position amid evolving regulations in Israel's medical cannabis sector.
Read more →INCRNOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 14 2023 NOTICE IS HEREBY GIVEN that a special meeting (the " Meeting ") of the shareholders of Intercure Ltd. (the " Company ") will be held at the offices o
Intercure Ltd. has announced a special meeting of shareholders scheduled for August 14, 2023, to be held in Bnei Brak, Israel. The primary agenda item is to consider a resolution regarding the company's voluntary delisting from the Toronto Stock Exchange and the dual listing on the Nasdaq Global Market. Shareholders recorded as of July 14, 2023, will be eligible to vote and can either attend in person or vote via proxy. Key instructions for proxy submissions have been outlined for registered and beneficial owners in different regions.
Read more →INCR▲ +7.6%on this news
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE NEW YORK, TORONTO, and
InterCure Ltd. has announced its decision to voluntarily delist its shares from the Toronto Stock Exchange (TSX) while maintaining listings on the NASDAQ and TASE. The company's board determined that the low trading volume on the TSX does not justify its continued listing, suggesting a strategic move to enhance operations. InterCure intends to remain a reporting issuer in Canada and will seek shareholder approval at a special meeting scheduled for August 14, 2023. This decision aligns with the company's position as a leading competitor in the cannabis industry.
Read more →INCRInterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger NEW YORK, TORONTO, and
InterCure Ltd. has provided an update on the lawsuit it filed against Cann Pharmaceuticals following the termination of their merger agreement. The company rejected Cann Pharmaceuticals' counterclaim which demands the consummation of the original agreement or damages. InterCure is determined to pursue all legal avenues to recover the funds loaned to Cann during their negotiations. The situation remains contentious and highlights the ongoing disagreements between the two parties.
Read more →INCRInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA (1) of $6 Million S
InterCure Ltd. reported a record revenue of $40 million for the first quarter of 2023, reflecting a 22% year-over-year growth. The company also announced an annualized revenue run rate of $159 million along with an adjusted EBITDA of $6 million. Despite the positive financial results, challenges included a decrease in gross margin and delays in pharmacy licensing. InterCure has plans for ongoing expansion and is addressing market conditions affecting certain product lines.
Read more →INCR▲ +5.5%on this news
Intercure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel NEW YORK, TORONTO, and
InterCure Ltd. announced that an application for a class action has been filed against it and 25 other cannabis companies in Israel. The class action alleges violations of advertising prohibitions in the regulations governing medical cannabis. The company is currently assessing the application for its likelihood of acceptance amid these allegations. InterCure, recognized as a leading player in the cannabis sector, has to navigate this legal challenge while maintaining its growth trajectory.
Read more →INCR▲ +5.5%on this news
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary NEW YORK, TORONTO, and
InterCure Ltd. announced that a lawsuit was filed against it by minority shareholders of its subsidiary, Cannolam, due to ongoing management disputes. The lawsuit was submitted to the Tel Aviv-Jaffa District Court, and InterCure believes the claims are without valid legal basis. The company intends to evaluate all legal options available and is committed to vigorously defending its interests amidst this conflict.
Read more →INCR▲ +6.8%on this newsshared move
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legend
InterCure Ltd. has partnered with TYSON 2.0, led by Mike Tyson, to distribute cannabis products in Israel, Australia, the UK, Germany, and other EU countries. This collaboration grants InterCure exclusive rights to cultivate and distribute TYSON 2.0's cannabis products, thereby enabling both companies to leverage each other's strengths in the growing cannabis market. The deal is seen as a strategic move that aligns with the rapid growth in legal cannabis markets in these regions. The partnership also allows InterCure to use TYSON 2.0's intellectual property and branding in its operations.
Read more →INCR▲ +25.7%on this news
InterCure Announces Reschedules 2022 Full Year Results Conference Call NEW YORK, TORONTO, and
InterCure Ltd. has announced the rescheduling of its conference call to discuss the financial results for the year ended December 31, 2022. Originally planned for April 3, 2023, the call will now take place on April 4, 2023, at 4:30 P.M. Eastern time. The postponement is attributed to unforeseen technical issues. InterCure is recognized as a leading cannabis company, emphasizing its growth within the international market.
Read more →INCRInterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17
InterCure Ltd. announced record results for the fourth quarter and fiscal year ending December 31, 2022, showcasing a revenue of $150 million and an adjusted EBITDA of $32 million. The company reported a significant net income of $17 million and strong cash flow from operations. Furthermore, InterCure expanded its market presence by increasing its product offerings and opening new locations. The company is focused on navigating regulatory challenges while continuing to build shareholder value and improve patient care.
Read more →INCRIntercure Files Lawsuit Against Cann Pharmacuticals to Recover Funds Following Failed Merger NEW YORK, TORONTO, and
InterCure Ltd. has initiated a lawsuit against Cann Pharmaceuticals to recover funds following a failed merger agreement. This legal action comes after InterCure provided financial support and services to Cann Pharmaceuticals, which did not meet the conditions necessary to complete the merger. As a result, InterCure seeks to enforce its rights to recover the loans and investments made. Previous disclosures indicated a lack of agreement on key merger terms, leading to the termination of the agreement on January 31, 2023.
Read more →INCRInterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better) NEW YORK, TORONTO, and
InterCure Ltd. has announced the termination of its acquisition agreement with Cann Pharmaceutical Ltd., known as Better, due to unmet closing conditions. The agreement, initially established on February 13, 2022, was set to finalize by January 31, 2023, but did not meet the conditions required for completion. As a result, InterCure intends to pursue recovery of significant amounts owed by Better, utilizing all legal means available. This development showcases potential challenges in the cannabis sector, highlighting the complexities of mergers and acquisitions in the industry.
Read more →INCRInterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske" Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, In
Partnership Agreement with Winning Cannabis Brand "Binske" Global Pharmaceutical Cannabis Company, InterCure, entered into agreement with Praetorian Global, Inc. to license, manufacture and the Florida-based cannabis brand "Binske" YORK, TORONTO, and HERZLIYA, Israel - Decem
Read more →INCRInterCure Announces the Withdrawal of a Class Action Lawsuit against it NEW YORK, TORONTO, and
Announces the Withdrawal of a Class Action Lawsuit against it YORK, TORONTO, and HERZLIYA, Israel - December 5, 2022 - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is pleased to announce the withdrawal of a class action l
Read more →INCRUpdate regarding Better Transaction NEW YORK, TORONTO, and HERZLIYA, Israel -November, 23, 2022 InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Company ") is hereby providin
regarding Better Transaction YORK, TORONTO, and HERZLIYA, Israel -November, 23, 2022 InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an update that further to the announcement from February 16, 2022, rega
Read more →INCR▼ -5.6%on this news
Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure wi
and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years ON, and HERZILA, ISRAEL,
Read more →INCRIntercure Ltd. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS As of
CONSOLIDATED INTERIM FINANCIAL STATEMENTS of September 30, 2022 CONSOLIDATED INTERIM FINANCIAL STATEMENTS of September 30, 2022 Page Condensed Consolidated Interim Statements of Financial Position 3-4 Condensed Consolidated Interim Statements of Profit or Loss and Other Comp
Read more →INCR▼ -8.2%on this news
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 15, 2022 NOTICE IS HEREBY GIVEN that an annual and special meeting (the " Meeting ") of the shareholders of Intercure Ltd. (the " Company ") wi
OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 15, 2022 IS HEREBY GIVEN that an annual and special meeting (the "Meeting") of the shareholders of Intercure Ltd. (the "Company") will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor
Read more →INCR▼ -5.2%on this news
InterCure Begins 2022 with Record Breaking First Quarter Financial Results Record revenue of $34 1 million in the first quarter of 2022 Adjusted EBITDA 2 increased almost 110% year-over-year to $8 million Net income of $
Begins 2022 with Record Breaking First Quarter Financial Results revenue of $341 million in the first quarter of 2022 EBITDA2 increased almost 110% year-over-year to $8 million million for the Q1 of 2022 compared to $2 million in Q1 of 2021 consecutive quarter of positive cas
Read more →INCRANNUAL INFORMATION FORM for the year ended
the year ended December 31, 2021 INTRODUCTION 1 CORPORATE STRUCTURE 6 GENERAL DEVELOPMENT OF THE BUSINESS 7 DESCRIPTION OF THE BUSINESS 11 REGULATORY OVERVIEW 27 RISK FACTORS 33 DIVIDENDS 59 DESCRIPTION OF CAPITAL STRUCTURE 59 ISSUED SHARES HELD BY INTERESTED PARTIES 61 MARKET F
Read more →INCRInterCure Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth Estimated revenue reaches over CAD$31 million (a record NIS 77 million) Anticipates continued increases in adjusted operat
Reports Record Preliminary 2021 Fourth Quarter Revenue - 3 Times YoY and 24% QoQ Growth revenue reaches over CAD$31 million (a record NIS 77 million) continued increases in adjusted operating profit and EBITDA growth expected to continue throughout 2022 Canada, and Herzliya,
Read more →INCRINTERCURE LTD. ("Intercure") Extraordinary General Meeting of Shareholders of Intercure Ltd. held on
General Meeting of Shareholders of Intercure Ltd. held on December 30, 2021 to National Instrument 51-102 Continuous Disclosure Obligations Section 11.3 ISRAEL - (December 30, 2021) Intercure Ltd. (the "Company") announces today the results of the Annual General Meeting of sh
Read more →INCRInterCure Announces European Expansion with International Cannabis Brand Cookies Leading Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022 NEW YORK, TO
Announces European Expansion with International Cannabis Brand Cookies Global Cannabis Company InterCure Partners with Cookies to Open Retail Locations in Austria and the U.K. in Early 2022 YORK, TORONTO, and HERZLIYA, Israel -Dec. 2, 2021 - InterCure Ltd. (NASDAQ: INCR) (TSX:
Read more →INCRInterCure Expands Pharmacy Chain in Israel; Surpasses One-Ton Medical Cannabis Products Dispensed Per Month With addition of four new pharmacies, InterCure's dedicated chain GIVOL now has 20 locations across Israel NEW Y
Expands Pharmacy Chain in Israel; Surpasses One-Ton Medical Cannabis Products addition of four new pharmacies, InterCure's dedicated chain GIVOL now has 20 locations across Israel YORK, TORONTO, and HERZLIYA, Israel - November 15, 2021 - InterCure Ltd. (NASDAQ: INCR) (TSX: IN
Read more →INCR▲ +7.6%on this news
InterCure Announces Record Preliminary Third Quarter Revenue of CAD$24 million - 3 Times YOY and 36% QOQ Growth Achieved a number of firsts and records including: Seventh consecutive quarter of double-digit revenue growt
Announces Record Preliminary Third Quarter Revenue of CAD$24 million - 3 Times YOY and 36% QOQ Growth a number of firsts and records including: consecutive quarter of double-digit revenue growth consecutive quarter of high digit accelerated profitable growth trading on NASDAQ
Read more →INCRInterCure Announces Record-Breaking Second Quarter Financial Results With 4 Times YOY Revenue Growth Achieved record revenue of NIS 45 million (over CAD$17 million), an increase of 400% year-over-year and 3 7 % quarter-o
Announces Record-Breaking Second Quarter Financial Results With 4 Times YOY Revenue Growth record revenue of NIS 45 million (over CAD$17 million), an increase of 400% year-over-year and 37% quarter-over-quarter quarterly run-rate Q2 Pro Forma1 revenues of NIS 55 million (over C
Read more →Competitive Position
How INCR ranks across every disease it competes inCompetitive Position is a premium feature
See how INCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial